Zheng Wei

Biography

Dr. Zheng Wei has over 20 years of experience in the biopharmaceutical industry and 15 years in GPCR drug discovery and development. Prior to co-founding Suzhou Connect Biopharma, Dr. Zheng was Director of Immunology at Arena Pharmaceuticals where he oversaw the discovery programs in the inflammation therapeutic area. Prior to joining Arena, Dr Zheng was a founding scientist and Assistant Director of Biology at ChemoCentryx. During his 10 year tenure at ChemoCentryx, he was responsible for the invention and implementation of the company’s proprietary technology platform; he initiated and led two drug discovery programs that yielded drug candidates that entered Phase II and Phase III clinical trials, including Vercirnon for inflammatory bowel disease (IBD) that was licensed to GSK. Prior to ChemoCentryx, he was a scientist at Ligand Pharmaceuticals. He also conducted research on human antibody gene rearrangement at Stanford University School of Medicine. Dr. Zheng is an inventor of 14 issued patents several pending patent applications on GPCR related therapeutic agents and technologies. He received his Ph.D. in Biochemistry and Molecular Biology from the University of California at Davis.

Research Interest

Business, Management, Toxicology, Pharmacology